Initial high-efficacy disease-modifying therapy in multiple sclerosisMathias Due Buron, Melinda Magyari, Peter Vestergaard Rasmussen et al.|Neurology|2020Cited by 160
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Stella Hughes et al.|JAMA Neurology|2023Cited by 62
Comparative effectiveness of teriflunomide and dimethyl fumarateMathias Due Buron, Melinda Magyari, Thor Ameri Chalmer et al.|Neurology|2019Cited by 45
Real-world outcomes for a complete nationwide cohort of more than 3200 teriflunomide-treated multiple sclerosis patients in The Danish Multiple Sclerosis RegistryViktoria Papp, Melinda Magyari, Mathias Due Buron et al.|PLoS ONE|2021Cited by 20
Patterns and predictors of multiple sclerosis phenotype transitionLuigi Pontieri, Melinda Magyari, Nupur Greene et al.|Brain Communications|2024Cited by 8